
 Scientific claim: Increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation induced locomotor deficits. 
 Participant Dynamics: Peer vs. Peer 
 Contextual Arena: The Persuasive Arena (goal: to win over an audience) 
 Interaction Trigger: An External Mandate (a new law, policy, or trend) 
 Dialogue Objective: To Reach a Decision (choose or reject an action) 
```
Speaker 1: Recent studies have shown that increased microtubule acetylation exacerbates LRRK2 Roc-COR domain mutation-induced locomotor deficits. It's becoming a hot topic since the new funding regulations are pushing for targeted research areas.

Speaker 2: Absolutely, and it's crucial we decide whether to pivot our research focus to this area. The implications could be significant for Parkinson’s research.

Speaker 1: Right, but the question is, should we align our grant proposals accordingly? We need to convince our peers that this is the direction worth taking.

Speaker 2: Well, consider the evidence. The study indicates a clear link between acetylation and motor function deterioration in the presence of LRRK2 mutations. If we can target this pathway, the therapeutic potential is enormous.

Speaker 1: I agree, but some colleagues argue that the current evidence base is too narrow. They worry about putting all our eggs in one basket, especially with the funding mandate demanding fast results.

Speaker 2: That’s a valid concern, but isn't that the nature of scientific exploration? If we don’t explore these promising avenues, we risk stagnation. Plus, the new policy is designed to foster innovation.

Speaker 1: True, but we need a strategic approach to convince the board. What if we propose a dual study—one focusing on acetylation's role in LRRK2 mutations and another on alternative pathways?

Speaker 2: That could work. It shows adaptability and thoroughness. We can demonstrate a comprehensive understanding while still focusing on the promising acetylation pathway.

Speaker 1: Exactly. We need to ensure our proposal highlights both innovation and feasibility, aligning with the new funding directives. 

Speaker 2: So we’re agreed? We’ll draft a proposal that covers both angles and presents a balanced case to the review panel.

Speaker 1: Yes, let's do it. I’ll start compiling the relevant data. We need to act swiftly before the next grant cycle.

Speaker 2: Perfect. Let’s meet tomorrow to finalize our strategy.
```